UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Until when will Kolon keep lying about Invossa?
by Jeong Sae-im
2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
by Jeong Sae-im
2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
by Jeong Sae-im
2019-05-30 13:28
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
by Kim Yun-mi
2019-05-29 12:35
Invossa poses almost no safety threat: regulator
by Lee Hye-seon
2019-05-28 16:02
라인
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
by Lee Han-soo
2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’
by Jeong Sae-im
2019-05-24 19:34
‘Kolon’s extra data insufficient to explain Invossa mislabeling’
by Lee Hye-seon
2019-05-23 14:51
Prosecutors seek arrest warrant of Samsung BioLogics CEO
by Lee Han-soo
2019-05-23 11:19
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
by Jeong Sae-im
2019-05-22 11:59
라인
Legislator, activists call for revoking Invossa license, conducting probes
by Jeong Sae-im
2019-05-21 16:03
Kolon to follow 3,700 Invossa-treated patients for 15 years
by Jeong Sae-im
2019-05-17 15:38
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
by Jeong Sae-im
2019-05-17 13:21
CHA Biotech’s operating income plunges 92% in Q1
by Jeong Sae-im
2019-05-16 13:41
KangStem Biotech completes stem cell drug plant
by Jeong Sae-im
2019-05-16 11:27
라인
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit
by Jeong Sae-im
2019-05-14 14:10
Celltrion’s operating income down 33% in Q1
by Jeong Sae-im
2019-05-09 15:26
If Invossa license gets revoked, Kolon should return $13 million to Mundipharma
by Jeong Sae-im
2019-05-08 15:33
Inspection will clear all suspicions over Invossa: TissueGene
by Jeong Sae-im
2019-05-08 14:32
Kolon might have covered up Invossa mislabeling for 2 years
by Jeong Sae-im
2019-05-07 15:55
-
이전
11
12
13
14
15
16
17
18
19
20
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top